Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.

Ikemura K, Inoue K, Mizutani H, Oka H, Iwamoto T, Okuda M.

Eur J Pharmacol. 2012 Sep 5;690(1-3):192-201. doi: 10.1016/j.ejphar.2012.06.031. Epub 2012 Jun 30.

PMID:
22749977
2.

Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.

Ikemura K, Urano K, Matsuda H, Mizutani H, Iwamoto T, Okuda M.

J Pharmacol Exp Ther. 2009 Jan;328(1):249-55. doi: 10.1124/jpet.108.145581. Epub 2008 Oct 8.

3.

Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.

Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K.

Biochem Pharmacol. 2006 Oct 16;72(8):1042-50. Epub 2006 Aug 30.

PMID:
16939683
4.

Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.

Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A.

J Pharm Pharmacol. 2004 Oct;56(10):1259-66.

PMID:
15482640
5.

Renoprotective effect of trolox against ischaemia-reperfusion injury in rats.

Wongmekiat O, Thamprasert K, Lumlertgul D.

Clin Exp Pharmacol Physiol. 2007 Aug;34(8):753-9.

PMID:
17600552
6.

Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.

Fujita T, Yasuda S, Kamata Y, Fujita K, Ohtani Y, Kumagai Y, Majima M.

J Pharmacol Exp Ther. 2008 Nov;327(2):592-9. doi: 10.1124/jpet.108.142091. Epub 2008 Aug 25.

7.

Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.

Saitoh H, Saikachi Y, Kobayashi M, Yamaguchi M, Oda M, Yuhki Y, Achiwa K, Tadano K, Takahashi Y, Aungst BJ.

Eur J Pharm Sci. 2006 May;28(1-2):34-42. Epub 2006 Feb 2.

PMID:
16457995
8.
9.

Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.

Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K.

Drug Metab Pharmacokinet. 2005 Oct;20(5):324-30.

10.

Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.

Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K.

Int J Pharm. 2006 Feb 17;309(1-2):81-6. Epub 2005 Dec 27.

PMID:
16384676
11.

Effects of liver fibrosis on verapamil pharmacokinetics in rats.

Chen M, Xu D, Hu XL, Wang H.

Clin Exp Pharmacol Physiol. 2008 Mar;35(3):287-94. Epub 2007 Oct 31.

PMID:
17973928
12.

Trolox C ameliorates hepatic drug metabolizing dysfunction after ischemia/reperfusion.

Eum HA, Lee SH, Lee SM.

Arch Pharm Res. 2002 Dec;25(6):940-5.

PMID:
12510851
13.

Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure.

Shibata N, Inoue Y, Fukumoto K, Nishimura A, Fukushima K, Yoshikawa Y, Spiteller G, Takada K.

Biol Pharm Bull. 2004 Mar;27(3):384-91.

14.

Effect of thymoquinone on hepatorenal dysfunction and alteration of CYP3A1 and spermidine/spermine N-1-acetyl-transferase gene expression induced by renal ischaemia-reperfusion in rats.

Awad AS, Kamel R, Sherief MA.

J Pharm Pharmacol. 2011 Aug;63(8):1037-42. doi: 10.1111/j.2042-7158.2011.01303.x. Epub 2011 Jun 8.

PMID:
21718287
15.
16.

[Effect of CYP3A and P-glycoprotein on the absorption of buagafuran in rat intestinal lumen].

Sheng L, Tan W, Hu JP, Chen H, Li Y.

Yao Xue Xue Bao. 2010 Jan;45(1):43-8. Chinese.

PMID:
21351448
17.

Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.

Liu Y, Luo X, Yang C, Yang T, Zhou J, Shi S.

Mol Med Rep. 2016 Oct;14(4):3073-85. doi: 10.3892/mmr.2016.5616. Epub 2016 Aug 9.

18.
19.

Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats.

Hirunpanich V, Katagi J, Sethabouppha B, Sato H.

Drug Metab Dispos. 2006 Feb;34(2):305-10. Epub 2005 Nov 18.

20.

Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.

Sugioka N, Fujimoto K, Tanaka Y, Fukushima K, Ito Y, Kokuhu T, Okamoto M, Yoshimura N, Takada K.

Drug Metab Lett. 2009 Aug;3(3):152-61. Epub 2009 Aug 1.

PMID:
19702545

Supplemental Content

Support Center